South Africa’s Strategic Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce a structured, data-driven framework that fundamentally changes how public institutions acquire goods and services. For pharmaceutical, biotech and medtech companies, the...

Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression. ODAC Backs Targeted Therapy The ...

EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...

Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...

Rui Santos Ivo, President of the INFARMED Board of Directors and Chair of the European Medicines Agency (EMA) Management Board, emphasized the need for regulatory frameworks innovation during the opening session of the Regulatory Affairs Professionals Society (RAPS) Euro Convergence 2026 conferen...

The MFN drug pricing savings under the Trump Administration’s voluntary framework total hundreds of billions of dollars. The policy has already secured agreements with 17 manufacturers and is projected to deliver $529 billion in U.S. savings over ten years from new drugs, plus an additional $64.3...